BioArctic AB (publ) (NASDAQ STOCKHOLM: BIOA B) today announced that the U.S. Food and Drug Administration (FDA) has approved BioArctic's partner Eisai's ...
The healthcare sector has struggled to deliver worthwhile returns for investors since 2021, weighed down by several headwinds ...
Celularity Inc., a biotechnology firm specializing in pharmaceutical preparations, has terminated a significant agreement ...
Larimar Therapeutics, Inc. (NASDAQ:LRMR), with a market capitalization of $228 million, is a clinical-stage biopharmaceutical ...
There are lots of interesting companies that make Bedford their home. Here is a quick recap of what’s happening around town ...
Hosted on MSN2d
Biotech Market Forecast: Top Trends for Biotech in 2025The biotech sector in 2025 presents a landscape brimming with both opportunities and challenges. The industry is being shaped ...
Stifel analysts increased their price target for Disc Medicine (NASDAQ:IRON) shares to $94.00, up from the previous $90.00. Currently trading at $57.07 with a market capitalization of $1.7 billion, ...
Harmony Biosciences' Wakix shows promise for significant revenue growth. Find out why HRMY stock’s profitability and pipeline ...
Revelation Biosciences Inc. (REVB) stock has plummeted to a 52-week low, touching down at $0.28, with a market capitalization ...
Ascentage Pharma Group (AAPG) (AAPGV) (OTCPK:ASPHF), which is backed by Takeda (NYSE:TAK), has priced a $126M U.S. initial public offering. The China-based drug developer priced 7.33M shares at $17.25 ...
H.C. Wainwright's valuation of Microbot Medical (NASDAQ:MBOT) stands at an estimated market value of $255 million, or $9 per share, which underpins the revised price target. The current market ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback